^(223)RaCl_(2)用于去势抵抗性前列腺癌骨转移治疗的临床研究进展及体内减毒  

The Clinical Research Progress and in vivo Poison Reduction of^(223)RaCl_(2)inTreating Bone Metastases of Castration-resistant Prostate Cancer

作　　者：薛帅 李丹妮 白庆云[1] 李潇 XUE Shuai;LI Danni;BAI Qingyun;LI Xiao(School of Chemistry and Bioengineering,Yichun Unvisity,Yichun 336000,China;Department of Nuclear Medicine,Shanghai Changhai Hospital,Shanghai 200433,China)

机构地区：[1]宜春学院化学与生物工程学院,江西宜春336000 [2]上海长海医院核医学科,上海200433

出　　处：《标记免疫分析与临床》2023年第5期876-880,共5页Labeled Immunoassays and Clinical Medicine

基　　金：江西省教育厅科技项目(编号:GJJ211640);国家自然科学基金(编号:82202216)。

摘　　要：^(223)RaCl_(2)被批准用于治疗患有去势抵抗性前列腺癌(CRPC)、有症状的骨转移和无已知内脏转移的患者,适用于提高去势抵抗性前列腺癌骨转移患者的生存率。用于核素治疗的骨沉积类放射性药物长期以来一直用于缓解骨转移患者的疼痛,同时α发射体223 Ra的寻骨特性和有利的物理特性使其在Ⅲ期试验ALSYMPCA中展现了额外的生存优势。目前,提高^(223)RaCl_(2)的生物利用度和减低胃肠道的辐射剂量的努力方向是降低^(223)RaCl_(2)在胃肠道的不良沉积。本文就^(223)RaCl_(2)在转移性去势抵抗性前列腺癌(mCRPC)中的作用机制和临床进展作一综述,重点讨论^(223)RaCl_(2)的生物安全性和利用其化学特性进行体内减毒的研究进展。^(223)RaCl_(2)was approved to treat patients with castration-resistant prostate cancer(CRPC),symptomatic bone metastasis patients without known visceral metastases,and therefore was applied to increase the survival rate of patients with bone metastases for castration-resistant prostate cancer.Bone-deposition-like radiopharmaceuticals for nuclide therapy have long been used for pain palliation in patients with bone metastases.Meanwhile,the bone-seeking properties and good physical characteristic of alpha emitter 223 Ra have shown additional survival advantages in the phase Ⅲ trial ALSYMPCA.Currently,the direction of the field to improve the bioavailability of^(223)RaCl_(2)and reduce the radiation dose in the gastrointestinal tract is to reduce the adverse deposition of^(223)RaCl_(2)in the gastrointestinal tract.This paper reviews the mechanism and clinical progress of^(223)RaCl_(2)in metastatic castration-resistant prostate cancer(mCRPC)with emphasis on the biosafety and the research evolution of in vivo poison reduction utilizing the chemical properties of^(223)RaCl_(2).

关 键 词：^(223)RaCl_(2) mCRPC 胃肠道 骨转移 骨骼相关事件 

分 类 号：R815.3[医药卫生—放射医学]